Although studies have investigated the epidemiology of patients with atrial fibrillation (AF), burden of illness research in Japan is scarce. The aim of the current study was to assess the patient characteristics, medication use, and comorbidities of an AF sample from a representative data source in Japan to make broad cross-region comparisons. The 2008 Japan National Health and Wellness Survey (NHWS) datasets were used in this study. The NHWS is an Internet-based survey administered to the adult population in Japan using a random stratified sampling framework to ensure demographic representativeness. Only patients who reported a diagnosis of AF (N=565) in these datasets were included in the analyses. Demographics, health characteristics, stroke risk (using the CHA2DS2-VASc score), and comorbidities were all assessed.
• Recent publications using data from the United States (US) and Europe (EU) have lifted the veil on atrial fibrillation (AF) patients' characteristics and highlighted existing unmet needs.
• In the US, LaMori and colleagues (2011) 1 found that nearly 81% of patients with AF are either at moderate (CHADS2=1) or high risk (CHADS2=2+) for a future stroke with only 71% of all patients taking a prescription medication for their condition and 43% using an anticoagulant.
• In Europe, Gupta and colleagues (2010) 2 , using the same risk score, found that 61% of AF patients are at moderate-to-high risk of stroke with only 1 in 5 high-risk patients taking warfarin.
Introduction
• The aim of the current study was firstly to assess the patient characteristics, medication use, and comorbidities of an AF sample from a representative data source in Japan and secondly to enable broad cross-region comparisons.
Objective Measures

Sociodemographics and health characteristics
• Age, sex, education, employment, annual household income, and out-of-pocket costs for medications and physician visits were assessed.
• Smoking history, alcohol use, exercise behavior, weight (in kilograms), and body mass index (underweight, normal weight, overweight, obese, decline to answer) were also included.
AF history
• Years diagnosed, stroke risk (using the CHA2DS2-VASc score), symptom severity (mild, moderate, or severe), symptom frequency (1 episode vs. 2 or more episodes lasting at least a week), and treatments used for AF were all assessed.
Comorbidities
• The Charlson comorbidity index 5 (CCI) was calculated based on self-reported comorbidities. Comorbidities were also organized by organ system in the same way as done in previous literature 1 .
Data source
• The current study used data from the Japan National Health and Wellness Survey (NHWS; Kantar Health, New York, NY), an annual, cross-sectional health survey of adults aged 18 years or older.
• Potential respondents to the NHWS are recruited through an existing web-based consumer panel.
• Using a stratified random sample framework (with quotas based on gender and age), the demographic composition of each year's Japan NHWS sample is comparable to that of the Japanese adult population as reported by the 2008 projections from the Japan Ministry of Internal Affairs & Communications 4 .
• Data from the 2008, 2009, and 2010 Japan NHWS were combined and used for this project. In instances where the same respondent completed more than one of these surveys, only the most recent data point was included so as to avoid non-unique responses.
Sample
• A total of 60,015 unique respondents completed the 2008, 2009, or 2010 Japan NHWS. Of these respondents, only patients who reported a physician diagnosis of AF (N=565) were included in the analyses.
Methods
• The mean age was 64.7 years (standard deviation [SD]=11.4), with patients having been diagnosed for 10.4 years (SD=10.6). Largely because of their age, most patients were currently not in the workforce (66.7%) (see Table 1 ).
• The average monthly out-of-pocket costs for physician visits and medications were ¥6,216 ($78) and ¥7,972 ($100), respectively.
• The majority of patients were male (83.5%) which is consistent with epidemiologic data 6 suggesting the prevalence of AF is 3 times higher among men. Table 3 . Frequency and severity of symptoms of patients with atrial fibrillation.
Results
• Nearly a fifth (19.1%) continued to smoke and more than two-fifths (41.1%) do not regularly exercise. The mean CCI score was 0.8 (SD=3.0) (see Table 2 ).
• The average bodyweight was 64.4 kilograms (Kg) (SD=10.9), in line with the J-ROCKET AF trial 7 (64Kg) and approximately 20% lower than international sources such as those reported in the ROCKET AF trial 7 (81.8Kg), RELY trial 8 (82.7Kg), ARISTOTLE trial 9 (82Kg), US NHWS (95Kg) and EU NHWS (87Kg) (see Figure 1 ).
• Most patients reported their AF symptoms as mild (55.0%), though over 50% reported that they typically have at least two episodes which last a week or more (see Table 3 ).
• Recent evidence 10 suggests that the CHA 2 DS 2 -VASc is more accurate than the CHADS 2 at identifying high risk AF patients. Based on this CHA 2 DS 2 -VASc score, 11.5% patients were of low stroke risk (CHA 2 DS 2 -VASc=0), while 35.4% and 53.1% were of moderate (CHA 2 DS 2 -VASc =1) and high risk (CHA 2 DS 2 -VASc=2+), respectively (see Figure 2 ).
• Despite this risk for stroke, only 68.0% of patients at high risk (CHA 2 DS 2 -VASc=2+) were currently being treated for AF with a prescription medication (anticoagulant, rhythm control medication, rate control medication, etc). Of all high-risk patients, 34.0% were using either warfarin or warfarin and aspirin.
• Patients with AF also reported a number of comorbidities including 87.1% with another cardiovascular condition such as hypertension (38.8%), 67.8% with a urological condition such as overactive bladder (28.7%), 37.3% with dyspepsia, and 32.7% with pain (see Figure 3) . A total of 8.0% of patients reported a previous myocardial infarction, while 2.7% and 1.8% reported chronic kidney disease (CKD) and moderate-to-severe renal disease, respectively.
• As with other regions, patients with AF in Japan were generally older and share with the healthcare system the burden of their healthcare costs. Also similar to other countries, over 50% of AF patients in Japan, through a combination of their behaviors (e.g., smoking) and health characteristics, are at high risk for a future stroke.
• However, the Japanese AF population is somewhat unique with respect to its lower body weight and its dramatic gender split.
• Despite being at high risk of a future stroke, 32% of patients are not treated for their AF with a prescription medication.
• Comorbidities like cardiovascular-related conditions (87%) or dyspepsia (37%) can complicate treatment decisions.
• These results suggest that, in addition to other considerations such as CHA 2 DS 2 -VASc score and patients comorbidities, weight is an important factor to consider for proper treatment of Japanese atrial fibrillation patients
Limitations
• All data from the NHWS is self-reported and no clinical verification of diagnoses or treatments were available. In addition, it is possible that the sample of AF patients differs in the real world.
• However, NHWS is nationally representative of the Japanese population with respect to age and gender and the demographic characteristics of the sample of AF patients match a previous publication by Inoue H et al 6 . 
Conclusions
